// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Functional characterisation of coagulopathy in isolated traumatic brain injury

C. Lindsay - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Traumatic brain injury

N/A

Fusogenic liposomes label human platelets without impacting normal platelet function

C. Kempster - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fibrinogen (IV)

Glycated albumin modulates the contact system with implications for the kallikrein-kinin and intrinsic coagulation systems

L. Hardy - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 1 diabetes mellitus

Human serum albumin

GPVI is a binding site for factor VIII on platelets

R. Sekar - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

FVIII

Haemorrhagic sub-phenotypes in hereditary haemorrhagic telangiectasia are associated with high impact DNA variants in platelet/coagulation genes responsible for general population bleeding disorders

K. Joyce - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Heavy menstrual bleeding from anticoagulation therapy significantly impacts on women’s quality of life – findings from the PERIOD programme of work

J. Patel - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Hemostatic results for up to 6 years following treatment with valoctocogene roxaparvovec, an AAV5-hFVIII-SQ gene therapy for severe hemophilia A

M. Laffan - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

Hemostatic Solution

Heparin and heparin proteoglycan-mimetics activate platelets via PEAR1 and PI3Kbeta

C. Kardeby - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Heparin

HMB-001 – a novel bispecific antibody accumulating and targeting endogenous FVIIa to activated platelets for subcutaneous prophylaxis in multiple bleeding disorders including Glanzmann Thrombasthenia

H. Ostergaard - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Glanzmann thrombasthenia

rFVIIa

Hydroxychloroquine as an adjunct treatment for patients with triple positive thrombotic antiphospholipid syndrome- a single centre experience

C. Crossette-Thambiah - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Antiphospholipid syndrome

Hydroxychloroquine

Identification and characterisation of ANKRD26-related thrombocytopenia in patients from the GAPP cohort.

H. Vyas - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Thrombocytopenia

N/A

Identification of non-coding genomic regions involved in the aetiology of bleeding, platelet, and thrombotic disorders.

L. Stefanucci - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Immune Medicated Thrombotic Thrombocytopenic Purpura relapse is associated with HLA-DRB1*15:01

M. Stubbs - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Thrombotic thrombocytopenic purpura

N/A

Impact of COVID-19 pandemic on VTE investigation and diagnosis rate in Belfast Health and Social Care Trust, Northern Ireland.

N. Sotiropoulou - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Impaired exercise capacity in Post-COVID syndrome: The role of VWF-ADAMTS13 axis

N. Prasannan - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Improving the provision of patient information regarding venous thromboembolism prevention at King’s College Hospital NHS Foundation Trust, London

G. Giron - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

In vitro monitoring of anti-coagulation therapy in whole blood using magnetic nanoparticles and susceptometry

A. Harper - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Bivalirudin

Increased platelet procoagulant activity driven by fibrin-GPVI interaction alters clot structure

J. Sandrin Gauer - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

eptifibatide

Innate and Adaptive Immune Responses to Adeno-Associated Viral Gene Therapy in the Severe Hemophilia A Dog Model

P. Batty - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

FVIII

Insulin resistance links to procoagulant clot properties in young adult with type 1 diabetes: a cross-sectional observation study

N. Kietsiriroje - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Type 1 diabetes mellitus

Fibrinogen (IV)

Copyright © 2026. QuantiNova All rights reserved